Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation

N/ACompletedNCT07297719

Carl Zeiss Meditec AG33 enrolled

Overview

Main evaluation of glistening at least 24 Months post-IOL implantation

Evaluation of glistening, visual outcomes and general safety after at least 24 Months post-IOL implantation

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cataract Senile

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients currently implanted with the CT LUCIA 621P IOL into the capsular bag in at least one eye and who participated in previous study "CT LUCIA 621P-BER-401-21"; 2. A minimum follow-up period of 24 months after the IOL implantation of the study eye (selected as the study eye in the previous study); 3. Patients willing and capable of providing informed consent; 4. Patients willing and capable of complying with visits and procedures as defined by this protocol. Exclusion Criteria: 1. Complications during cataract surgery with clinically significant impact; 2. Postoperative clinically significant corneal or retinal pathology as well as postoperative acute or chronic inflammatory ocular conditions (e.g. uveitis, iritis etc.); 3. Presence of clinically significant PCO with potential to limit the glistening evaluation; 4. IOL dislocation (the complete IOL is not stable fixated in the capsular bag); 5. Patients unable to meet the limitations of the protocol or likely of non-cooperation during the clinical investigation; 6. Patients whose freedom is impaired by administrative or legal order.

Locations (1)

Aier Eye Hospital of BoAo Hope City

Hainan, Hainan, China

Outcomes

Primary Outcomes

Glistening Count

Glistening count: Number of glistenings (=microvacuoles) in the illuminated field were counted by slit lamp examination at the study visit 24 months post IOL implantation of the study eye. Lower glistening counts indicate a better outcome (=fewer glistenings).

Time frame: single study visit conducted 24 months after IOL implantation of the study eye

Glistening Density Evaluation

Glistening density evaluation: Number of glistenings in the illuminated field were counted by slit lamp examination at the study visit 24 months post IOL implantation of the study eye. The number of glistenings were recorded and the density of microvacuoles per square millimeter (MV/mm²) was calculated. Lower glistening density values indicate better outcome (=fewer glistenings).

Time frame: single study visit conducted 24 months after IOL implantation of the study eye

Glistening Grading (Miyata Classification)

Glistening grading (Miyata classification): At the 24-month post-IOL implantation visit, the number of glistenings/microvacuoles (MV) in the illuminated field of the study eye was counted by slit-lamp examination. Glistening density was expressed as microvacuoles per square millimeter (MV/mm²) and graded using the Miyata Glistening Density Grading Scale (grades 0-3), where the minimum glistening level corresponds to grade 0 (\<25 MV/mm²) and the maximum to grade 3 (101-200 MV/mm²).0 corresponds to \<25 MV/mm² and grade 3 to 101-200 MV/mm². Lower Miyata grades indicate a better outcome (=fewer glistenings).

Time frame: single study visit conducted 24 months after IOL implantation of the study eye

Monocular Corrected Distance Visual Acuity (CDVA)

Monocular Corrected Distance Visual Acuity (CDVA) was assessed for each study eye using a standardized visual acuity chart under photopic conditions with the subject's best refractive correction in place. CDVA was recorded in logarithm of the Minimum Angle of Resolution (logMAR), with typical values ranging from about -0.3 (approximately 20/10 Snellen acuity) to 1.0 (approximately 20/200 Snellen acuity), where lower logMAR scores indicate better vision.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.